510(k) Report

510(k) · Cleared

Cleared

Oncentra Simulation 2.3

K090706510(k) TraditionalCleared Jun 15, 200990-day reviewClass II21 CFR 892.5840

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Nucletron Corporation · KPQ System, Simulation, Radiation Therapy

Cleared on Jun 15, 2009 as substantially equivalent to K033470 (Nucletron Corporation, 2004) and 1 other predicate after a 90-day review. Its family tree reaches back 2 generations to 1995.

Decided
Jun 15, 2009
Review
90 days
Class
Class II
Product code
KPQ
Recalls
None
Predicates
2

Its longest line of descent runs back 2 generations to K946128 (1995). 3 ancestors in all. No later device cites it as a predicate yet.

Other ancestors, by year cleared 1995: 1 other ancestorK946128 · Simulix-HP · Oldelft Corp. of America · 1995K033470 · Simulix Evolution · Nucletron Corporation · 20041995200020052010
Other ancestors, by generation 1 generation back: 1 other ancestor K033470 · Simulix Evolution · Nucletron Corporation · 2004K946128 · Simulix-HP · Oldelft Corp. of America · 19950
  1. Root · 2 generations backK946128 Simulix-HPOldelft Corp. of America · 1995
  2. 1 generation backK033470 Simulix EvolutionNucletron Corporation · 2004
  3. This deviceK090706 Oncentra Simulation 2.3Nucletron Corporation · 2009
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K946128Simulix-HPOldelft Corp. of America1995—
−1K033470Simulix EvolutionNucletron Corporation2004—
0 (this device)K090706Oncentra Simulation 2.3Nucletron Corporation2009—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199510
FIG. 1 — Lineage of K090706, 1995–2009Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in KPQ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K033470Simulix Evolution
Summary page 1
…substantially equivalent to the legally marketed predicate device cited in the table below: Nucletron BV Simulix Evolution k033470 Description: Oncentra Simulation 2.3 is a revision of the image handling software of the Simulix Evolution. This software has…
Nucletron Corporation2004—
*K954055HDX Digital Imaging System
Summary page 1
…Image Intensifier such as used on the Nucletron Radiotherapy simulators Simulix MC, Simulix HP and Simulix HQ. This makes it a replacement for the predicate device DTI (k954055). The PC based simulator workstation comes with functionality to support simulation procedures: Image acquisition === Pag…
Imacom, Inc.1995—

Also cleared against K033470: 1 other device →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 14 years and passes through 2 companies; a new generation was cleared every 8.7 years on median.
  • None of the 3 ancestors has a recall.
  • 1 other device also cites its predicate K033470.

How does its category compare?

All KPQ devices

KPQ System, Simulation, Radiation Therapy: FDA decisions, review times, recalls and adverse event reports over 20 years. 2009, this device’s year, is highlighted.

FDA decisions per year · KPQ

1in 2014

2007: 12008: 12009: 12010: 12013: 12014: 1
2007high 1 (2007) · low 0 (2011)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · KPQ

Too few KPQ 510(k)s in any year since 2007 to give a median.

Recalls per year · KPQ

1in 2014

2007: 62008: 32009: 12012: 12013: 12014: 1
2007high 6 (2007) · low 0 (2010)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · KPQ

1in 2020

2007: 172008: 122009: 72010: 102011: 122012: 112013: 12014: 32019: 12020: 1
2007high 17 (2007) · low 0 (2015)2025

MAUDE reports naming product code KPQ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—617
20081—312
20091—17
20101—010
20110—012
20120—111
20131—11
20141—13
20150—00
20160—00
20170—00
20180—00
20190—01
20200—01
20210—00
20220—00
20230—00
20240—00
20250—00
20260—0—

What is it indicated for?

Oncentra Simulation is an accessory to a radiation therapy simulation system which is intended to prepare patients for radiation therapy. The Simulator emulates the geometrical positions of radiation therapy treatment machines. Using conventional radiographic and fluorographic system, patients are positioned, filmed and marked to prepare them for their treatment.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K090706: Oncentra Simulation 2.3.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K090706

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026